Technology is starting to make it possible to
understand the complex interactions of the
microbiome in more detail.
Author: Robert Lavine
Fluence flies on to Nasdaq in $868m IPO
AES and Siemens’ energy storage venture, which also counts Qatar Investment Authority as an investor, priced the offering above its range.
Mozart tunes up with $55m series A
Eli Lilly, MRL Ventures Fund and Leaps by Bayer were among the participants in a round disclosed as the gastrointestinal disorder drug developer launched.
Exscientia expands IPO to over $350m
The cancer drug developer has closed an initial public offering which took place alongside a $160m SoftBank-led private placement.
Banma Technologies lands $465m
Alibaba and SAIC Motor helped provide fresh funding for the in-car system provider having formed it as a joint venture in 2015.
GV engages with nPlan
The risk management software developer secured $17.9m in a GV-led round that included LocalGlobe and Entrepreneur First.
1910 Genetics makes $22m date with Microsoft
M12 co-led a $22m series A round for the drug discovery technology developer with Playground Global, and both investors have taken board seats.
DexCare executes $20m series A
Providence’s health capacity management system has been spun off with $20m from investors including Providence Ventures and Kaiser Permanente Ventures
Pluang gets $20m funding placement
Returning corporate backer Go-Ventures took part in a pre-series B round for investment app developer Pluang as it looks to launch a government bond-focused product.
VoxSmart stocks up with $25m from Toscafund
HSBC-backed communications surveillance software developer has secured funding in a deal making Toscafund its lead investor.
Wangjiadu Foods wins series A funding
Fosun Xingyuan Innovation Fund, reportedly an existing investor, helped the processed food provider secure $15.3m.
Invstr inhales $20m in series A round
The Fibabanka-backed financial education provider has doubled its overall funding to $40m in a convertible note round.
Cyware secures $30m in series B funding
The cybersecurity software developer increased its overall funding to $43m in a Zscaler-backed series B round.
Variantyx picks IBM for $20m series C
IBM Ventures participated in a $20m round for the neurological disease diagnostics technology developer, a spinout from Tel Aviv University.